Potential new Botox use? Antidepressant; Medco to pay $7.9M in kickbacks case; Novartis touts promising Afinitor data;

@FiercePharma: NIH steps in with $9M Vanderbilt grant after rough season for flu vaccines. More | Follow @FiercePharma

@EricPFierce: ICYMI: #FDA blesses Baxter #saline plant in Spain for shipments to U.S. of 0.9% sodium chloride. Article | Follow @EricPFierce

@CarlyHFierce: Novo, Baxter spar over hemophilia patent amid ITC probe. Story | Follow @CarlyHFierce

> Add "potential antidepressant" to Botox's list of uses; the Allergan injection, best known as a cosmetic, is also approved for a variety of medical indications, including migraine. Report

> Medco Health Solutions, an Express Scripts ($ESRX) subsidiary, said it would pay $7.9 million to settle allegations that it engaged in a kickback scheme with AstraZeneca ($AZN). Report

> Novartis ($NVS) said its cancer drug Afinitor helped delay cancer growth in patients with advanced neuroendocrine tumors. Report

> Pulmonary embolism patients aren't properly screened for the pulmonary hypertension that might follow, a Bayer study found. Report

> Hospitals urged Congress not to change a drug discount program that's designed to help facilities that serve a large proportion of needy patients. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: MD Anderson Cancer Center partners to start breast cancer pilot project using Apple Watch. Report | Follow @FierceMedDev

@VarunSaxena2: St. Jude says alternative imaging system is optimal during stenting procedures. Story | Follow @VarunSaxena2

@EmilyWFierce: San Francisco startup reels in $30M for disease outbreak prediction tech. More | Follow @EmilyWFierce

> Philips collaborates with Dutch hospital to develop diabetic foot disease Dx. More

> Issue that led to halt of St. Jude TAVR trial no cause for concern, EuroPCR experts say. News

Biotech News

@FierceBiotech: Regeneron's arthritis drug aces Phase III with the FDA in sight. News | Follow @FierceBiotech

@JohnCFierce: What's your list of top 5 public biotechs? (Potential, management, smart execution) I'd put $BLUE in that group. Any other suggestions? | Follow @JohnCFierce

> Pfizer vet Gutiérrez-Ramos takes the reins at Synlogic. Article

> Bluebird offers a promising peek at a potential cure for sickle cell. More

Vaccines News

> Canadian biotech Medicago building $200M vaccine plant. Item

> Genocea's genital herpes vaccine succeeds in Ph II. More

> Takeda, Daiichi Sankyo ink flu vaccine distribution pacts with Japan's Kaketsuken. Story

> Zydus Cadila preps for big splash into India's vaccines market. Article

> U.K.'s PsiOxus scores $39M for colorectal cancer vaccine combo trial. Report

CRO News

> Quintiles' founders bank $770M in secondary offering. Item

> InVentiv invests in compliance as regulations shift for real-world studies. Story

> Quotient Clinical soars in its first year after a PE buyout. Report

> WuXi posts another big quarter as it faces a big decision. Article

Pharma Manufacturing News

> Hospira recalls solution marked as heparin. Item

> Zydus Cadila said to be buying Claris' sterile injectables biz as landscape morphs. Story

> Apotex recalling generic Zyprexa because the antipsychotic may be too weak. News

> Fund grows to $200M for victims of meningitis outbreak tied to compounder. Article

> Medicago building $200M plant to manufacture vaccines from plants. Report

Pharma Asia News

> Sinocare said to bid $1B for Bayer diabetes devices, piping Panasonic. More

> China academy plans clinical trials on artemisinin derivative aimed at lupus. News

> Japan eyes higher target for generics despite missing earlier aims. Article

> Gilead's Sovaldi faces renewed advocacy CL pressure, this time for China and Russia. Story

> Glenmark gets India nod on shares sales to foreign investors, Temasek in. Report

And Finally... CareFirst BlueCross BlueShield said a cyberattack compromised the data of 1.1 million current and former members. Report

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.